canrenone has been researched along with Essential Hypertension in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bestetti, A; D'Avino, M; Derosa, G; Felis, S; Gaudio, G; Guasti, L; Maffioli, P; Mugellini, A; Sala, C; Sarzani, R; Vanasia, M; Vulpis, V | 1 |
1 trial(s) available for canrenone and Essential Hypertension
| Article | Year |
|---|---|
Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Canrenone; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hydrochlorothiazide; Hypertension; Italy; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome | 2017 |